NiCox news from FierceBiotech
NewsNicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
ALSO NOTED: The WSJ profiles the FDA's lead regulator for cancer; Living Cell raises funds; new approach to gene therapy; and m
> The argument over the FDA's role in regulating cancer therapies often comes down to one man: Dr. Richard Pazdur, a veteran oncologist and chief of the agency's oncology office. Read more...
NicOx pushes new naproxen version for arthritis pain
The Wall Street Journal reports on the progress that NicOx is making advancing a new version of naproxen for relieving arthritis pain. The French biotech is looking for a marketing partner for the Read more...
ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc
> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis. Read more...
ALSO NOTED: Renovis' CEO steps down; Isis gains $5M milestone; and much more...
> Chutes & Ladders: Corey Goodman is stepping down as CEO of Renovis as the company completes its Read more...
ALSO NOTED: NicOx gains $5M from Merck; King sells manufacturing facility; and much more...
> Merck has begun clinical trials to develop nitric oxide-donating antihypertensive agents, triggering a €5 million milestone payment to NicOx. Read more...
ALSO NOTED: Dr. Reddy's takes a gamble on biogenerics; Coley receives $5M from Dynavax; and much more...> Brian Orelli of the Motley Fool profiles a risky move by generic drugmaker Dr. Reddy's Laboratories. Article > In New Jersey, the biotech industry is booming. Article > Coley will receive at least $5 million from Dynavax Technologies for the nonexclusive marketing rights to commercialize Coley's hepatitis B vaccine Heplisav. The therapy is in … Read more...MediVas partners with Pfizer on eye programsMediVas has teamed with Pfizer to develop new therapies for eye diseases. The pact will combine MediVas work in polymers with Pfizer's compounds. No financial terms were released. "We are confident that by combining Pfizer's compounds with our best in class polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye," said Kenneth Carpenter, MediVas' president and chief executive officer. - check out the … Read more...Press Release: NicOx SA Receives 5 Million Euro Payment From MerckPress Release: NicOx SA Receives 5 Million Euro Payment From Merck Read more...ALSO NOTED: FDA approves antibody; Nastech to raise $42M; MGI publishes data; and much more...> Archemix is gaining up to $10 million up front in fees and research funds in a new collaboration pact to develop aptamer cancer therapies with Germany's Merck KGaA. Archemix concentrates on aptamers, strings of nucleic acid that bind to proteins and disrupt the progression of disease. "This is the fourth major partnership we have formed over the past six months and is consistent with our strategy to enable partners to leverage aptamers as drugs on a target-by-target basis," Archemix … Read more... | Press ReleasesPRESS RELEASE: NicOx Says has Promising Results from Ferrer Deal NicOx Says has Promising Results from Ferrer Deal SOPHIA ANTIPOLIS, FRANCE -- Oct 2, 2007 -- October 2, 2007. www.nicox.com NicOx S.A. today announced the Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight